Neuphoria Therapeutics (NEUP) EPS (Basic) Growth (1y) (2024 - 2026)
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) EPS (Basic) Growth (1y) (2024 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Neuphoria Therapeutics | 463.74 Mn | 444.30 Mn | - | -104.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -104.48% |
| Dec 31, 2025 | 195.92% |
| Sep 30, 2025 | -1,130.95% |
| Jun 30, 2025 | -1,452.68% |
| Mar 31, 2025 | 505.38% |
| Dec 31, 2024 | 57.33% |
| Sep 30, 2024 | 85.29% |